RINVOQ
Identification of Rinvoq
| No description |
Google image searchProduct monograph
Active ingredient
upadacitinib, 30 MG
DIN: 02520893
Dosage form(s): TABLET (EXTENDED-RELEASE)
Route(s) of administration: ORAL
Schedule: Prescription
Company: ABBVIE CORPORATION
Date: 28-OCT-2021
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AF — Janus-associated kinase (JAK) inhibitors (ATC, ATC/DDD)
- L04AF03 — UPADACITINIB (ATC/DDD)
